Confirmed Speakers to date

Synthetic Organic Photochemistry in Batch and Flow



Prof. Kevin BOOKER-MILBURN (UNIVERSITY OF BRISTOL, Bristol, United Kingdom)

Making Molecular Prosthetics via Iterative Cross-Coupling with MIDA Boronates



Prof. Martin D. BURKE (UNIVERSITY OF ILLINOIS, Urbana, United States)

Oligonucleotide Synthesis Interfaced with Molecular Biology and Nanotechnology



Prof. Marvin CARUTHERS (UNIVERSITY OF COLORADO, Boulder, United States)

BETting on Epigenetic Targets: From Phenotypic Discovery to First Time in Man



Dr Chun-wa CHUNG (GLAXOSMITHKLINE, Stevenage, United Kingdom)

Versatile Synthetic Methods: Access to Bioactive Molecules



Prof. Janine COSSY (ESPCI PARISTECH, Paris, France)

Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture



Dr Simona COTESTA (NOVARTIS, Basel, Switzerland)

Highly Anti-inflammatory Dendritic Polyglycerol Sulfates - a Multiple Target Approach



Prof. Rainer HAAG (FREE UNIVERSITY BERLIN, Berlin, Germany)

Targeting Protein Surfaces Using Designed Proteomimetics



Prof. Andrew HAMILTON (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

A New Approach to Tuberculosis Research: The Lilly TB Drug Discovery Initiative



Dr Philip A. HIPSKIND (ELI LILLY & COMPANY, Indianapolis, United States)

Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to the Clinical Candidate AZD7687



Dr Petra JOHANNESSON (ASTRAZENECA, Mölndal, Sweden)

Harnessing Synergy Between Natural Products and Synthesis Towards Drug Discovery



Prof. Goverdhan MEHTA (UNIVERSITY OF HYDERABAD, Hyderabad, India)

New Strategies in Organic Synthesis: Recent Advances Based on Catalytic Reactions of Boron Reagents



Prof. James P. MORKEN (BOSTON COLLEGE, Chestnut Hill, United States)

P2X Receptors: ATP-Gated Ion Channels as Novel Drug Targets



Prof. Christa MÜLLER (UNIVERSITY OF BONN, Bonn, Germany)

Advances in Targeting Voltage-Gated Sodium Channels with Small Molecules



Dr Antonio NARDI (GRÜNENTHAL, Aachen, Germany)

Organic Molecules as Biological Probes...an exciting journey



Prof. Cristina NEVADO (UNIVERSITY OF ZURICH, Zurich, Switzerland)

Bitopertin (RG1678), a Potent and Selective Glycine Re-Uptake Inhibitor for the Treatment of Schizophrenia



Dr Emmanuel PINARD (F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Antibody Drug Conjugates for the Treatment of Cancer



Dr Paul POLAKIS (GENENTECH, San Francisco, United States)

Peptide Chemologics



Dr Lee ROBERTS (PFIZER, Sandwich, United Kingdom)

The Discovery of the Macrocyclic HCV NS3/4A Protease Inhibitor MK-5172



Dr Michael ROWLEY (MERCK RESEARCH LABORATORIES, Kriens, Switzerland)

The Design and Characterization of Targeted Covalent Inhibitors of Btk



Dr Eric SCHWARTZ (CELGENE AVILOMICS RESEARCH, Cambridge, United States)

From Organic Synthesis to Biomedical Sciences - from Polyhydroxybutyrate (PHB) to Cell-Penetrating Peptides



Prof. Dieter SEEBACH (ETH ZURICH, Zürich, Switzerland)

Engineering of Small Non-Antibody Protein Scaffolds as Novel Biopharmaceuticals: from Anticalins to PASylation



Prof. Arne SKERRA (TECHNICAL UNIVERSITY MUNICH, München, Germany)

Metal Catalyzed Arylation of Nucleophiles



Dr Marc TAILLEFER (ENSCM, Montpellier, France)

Discovery and Initial Clinical Results of [18F]-UCB-H, First PET Radiotracer Targeting Synaptic Vesicle 2A



Dr Anne VALADE (UCB, Braine-l'Alleud, Belgium)

Confirmed Oral Communications

EFMC Prize for a Young Medicinal Chemist in Academia Chemical Approaches to Biology and Therapeutics



Dr Gonçalo BERNARDES (INSTITUTO DE MEDICINA MOLECULAR, LISBON, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

EFMC Prize for a Young Medicinal Chemist in Industry
Free-Wilson and Structural Approaches to Co-Optimising Human and Rodent Isoform Potency for
11?-Hydroxysteroid Dehydrogenase Type 1 (11? -HSD1) Inhibitors



Dr Frederick GOLDBERG (ASTRAZENECA, Macclesfield, United Kingdom)

Novel Synthetic Chemical Chaperones as a New Basis For Amyotrophic Lateral Sclerosis (ALS) Treatment



Dr Arie-Lev GRUZMAN (BAR ILAN UNIVERSITY, Ramat Gan, Israel)

New Inhibitors of the Enzyme Isoprenylcysteine Carboxyl Methyltransferase (ICMT)



Prof. María del Mar MARTÍN-FONTECHA (COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

Fragment-Based Design of Inhibitors of The Antituberculotic Target 1-Deoxy-D-Xylulose-5-Phosphate Synthase Exploiting an Innovative Combination of NMR Techniques



Mrs Tiziana MASINI (UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Design, Synthesis and Application Of Fluorinated Amino Acids as Labels to Study the Membrane Active Peptides by Solid State 19F NMR



Dr Pavel MYKHAILIUK (ENAMINE LTD, Kyiv, Ukraine)

Rapid Kinase SAR Generation: an Integrated Approach to Synthesis, Screening and Molecular Design



Dr David PARRY (CYCLOFLUIDIC LTD, Welwyn Garden City Herts, United Kingdom)

Virtual Screening and Design of New Pharmaceutical Agents Using PASS Approach



Prof. Vladimir POROIKOV (INSTITUTE OF BIOMEDICAL CHEMISTRY, Moscow, Russia)

Discovery of Highly Potent S1P1 Receptor Antagonists with in vivo Efficacy



Dr Jean QUANCARD (NOVARTIS PHARMA, Basel, Switzerland)

Self-Immolative Spacers in Prodrug/Profluorophore Strategies: Determination of Kinetic Parameters for Release of Single or Multiple Substrates.

ASMC'13 Moscow

Confirmed Speakers



Dr Frédéric SCHMIDT (INSTITUT CURIE, Paris, France)

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors



Dr Graeme SMITH (VERTEX PHARMACEUTICALS, Cambridge, United States)

Synthetic Approach to Novel Melatonin Receptor Ligands



Mrs Maria VOLKOVA (MOSCOW STATE UNIVERSITY, CHEMISTRY DEPARTMENT, Moscow, Russia)